3--3-methyl-butan | 91819-34-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3--3-methyl-butan
• 英文别名: Methyl-t-butyl-t-amyl-amin；Isobutyl-methyl-<2-methyl-but-2-yl>-amin；NoName_3675；N-tert-butyl-N,2-dimethylbutan-2-amine
• CAS: 91819-34-0
• 化学式: C₁₀H₂₃N
• 分子量: 157.299
• InChiKey: HODGCVNTSLRUHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  叔戊基叔丁基胺 、 硫酸二甲酯 在 potassium carbonate 作用下， 生成 3--3-methyl-butan
  参考文献：
  名称：

  Highly Hindered Aliphatic Tertiary Amines

  摘要：

  DOI：

  10.1021/jo01068a036

文献信息

• PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Teijin Pharma Limited

  公开号：EP3305785A1

  公开（公告）日：2018-04-11

  The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

  本发明的目的是提供一种具有优异 CDK4/6 抑制活性的化合物。本发明是通式（I）代表的化合物或其药学上可接受的盐。
• Targeted protein degradation using a mutant E3 ubiquitin ligase
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10239888B2

  公开（公告）日：2019-03-26

  The present application provides bifunctional compounds of Formula I or II: or an enantiomer, diastereomer, or stereoisomer, or a pharmaceutically acceptable salt thereof, which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds of Formula (I) or (II) that link a mutant cereblon-binding moiety to a ligand that is capable of binding to a targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof. The present application also relates to polynucleotides or polypeptides of a mutant cereblon and methods of use thereof.

  本申请提供了式 I 或式 II 的双官能化合物： 或其对映体、非对映体或立体异构体，或其药学上可接受的盐，它们可作为蛋白质降解诱导分子。本申请还涉及通过使用式（I）或（II）的双官能化合物靶向降解内源性蛋白质的方法，该双官能化合物将突变脑龙结合分子与配体连接，配体能够与靶向蛋白质结合，可用于治疗增殖性疾病。本申请还提供了制造本申请化合物及其中间体的方法。本申请还涉及突变体脑龙的多核苷酸或多肽及其使用方法。
• Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
  申请人：Apellis Pharmaceuticals, Inc.

  公开号：US10875893B2

  公开（公告）日：2020-12-29

  In some aspects, the present invention provides compositions and methods of treatment comprising long-acting compstatin analogs. In some aspects, long-acting compstatin analogs comprise a clearance-reducing moiety attached to two compstatin analog moieties, wherein each compstatin analog moiety comprises a cyclic peptide comprising the amino acid sequence as set forth in SEQ ID NO: 28 extended by a lysine residue or a sequence comprising a lysine residue at the N-terminus, C-terminus, or both, wherein the lysine residue is separated from the cyclic portion of the peptide by a spacer comprising 8-amino-3,6-dioxaoctanoic acid (AEEAc) moiety, the clearance reducing moiety comprises a polymer, wherein each end of the polymer is linked to one of the compstatin analog moieties by way of a linker moiety that is or comprises a carbamate, and wherein the polymer is a PEG having an average molecular weight of about 40 kDa.

  在某些方面，本发明提供了包含长效氯司他丁类似物的组合物和治疗方法。在某些方面，长效氯司他丁类似物包括连接到两个氯司他丁类似物分子上的清除还原分子，其中每个氯司他丁类似物分子包括环肽，该环肽包含 SEQ ID NO：28 中所列的氨基酸序列，该序列由一个赖氨酸残基或在 N-末端、C-末端或两者处均包含赖氨酸残基的序列延伸，其中赖氨酸残基通过一个包含 8-氨基-3,6-二氧杂辛酸（AEEAc）分子的间隔物与肽的环状部分隔开、清除还原分子包括聚合物，其中聚合物的每一端都通过氨基甲酸酯或由氨基甲酸酯组成的连接分子与康肽类似物之一连接，其中聚合物是平均分子量约为 40 kDa 的 PEG。
• Nrf and HIF activators/HDAC inhibitors and therapeutic methods using the same
  申请人：THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

  公开号：US10934255B2

  公开（公告）日：2021-03-02

  Compounds that inhibit histone (HDACI) and/or activate Nrf2 and HIF, and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC and/or activation of Nrf2 and HIF provide a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.

  本发明公开了抑制组蛋白（HDACI）和/或激活Nrf2和HIF的化合物，以及含有这些化合物的组合物。此外，还公开了抑制 HDAC 和/或激活 Nrf2 和 HIF 可使癌症、神经退行性疾病、周围神经病变、神经系统疾病、脑外伤、中风、高血压、疟疾、自身免疫性疾病、自闭症、自闭症谱系障碍和炎症等疾病和病症受益的治疗方法。
• DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20190247509A1

  公开（公告）日：2019-08-15

  The present application provides bifunctional compounds of Formula (I): or Targeting Ligand or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for bromodomain-containing protein 9 (BRD9). The present application also provides methods for the targeted degradation of BRD9 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BRD9 which can be utilized in the treatment of disorders modulated by BRD9.